NovoCure Limited (NVCR) Insider Yoram Palti Sells 30,000 Shares of Stock

NovoCure Limited (NASDAQ:NVCR) insider Yoram Palti sold 30,000 shares of NovoCure Limited stock in a transaction on Monday, November 13th. The shares were sold at an average price of $17.13, for a total transaction of $513,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Yoram Palti also recently made the following trade(s):

  • On Thursday, November 9th, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The shares were sold at an average price of $18.25, for a total transaction of $547,500.00.
  • On Tuesday, November 7th, Yoram Palti sold 60,000 shares of NovoCure Limited stock. The shares were sold at an average price of $21.06, for a total transaction of $1,263,600.00.
  • On Thursday, November 2nd, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The shares were sold at an average price of $21.78, for a total transaction of $653,400.00.

NovoCure Limited (NVCR) traded up $0.55 during trading hours on Wednesday, hitting $17.60. 1,136,200 shares of the company traded hands, compared to its average volume of 854,933. The company has a current ratio of 5.90, a quick ratio of 5.30 and a debt-to-equity ratio of 0.83. NovoCure Limited has a 1-year low of $6.00 and a 1-year high of $22.30.

NovoCure Limited (NASDAQ:NVCR) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. The business had revenue of $50.10 million for the quarter, compared to analyst estimates of $43.45 million. NovoCure Limited had a negative net margin of 47.45% and a negative return on equity of 57.68%. The business’s quarterly revenue was up 130.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.39) EPS. sell-side analysts forecast that NovoCure Limited will post -0.63 EPS for the current year.

WARNING: This piece was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/15/novocure-limited-nvcr-insider-yoram-palti-sells-30000-shares-of-stock.html.

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its holdings in shares of NovoCure Limited by 61.7% during the 1st quarter. Bank of America Corp DE now owns 37,531 shares of the medical equipment provider’s stock valued at $305,000 after acquiring an additional 14,321 shares in the last quarter. Gotham Asset Management LLC acquired a new position in shares of NovoCure Limited during the 2nd quarter valued at $534,000. ETF Managers Group LLC acquired a new position in shares of NovoCure Limited during the 2nd quarter valued at $408,000. River & Mercantile Asset Management LLP lifted its holdings in NovoCure Limited by 9.9% in the 2nd quarter. River & Mercantile Asset Management LLP now owns 127,520 shares of the medical equipment provider’s stock worth $2,203,000 after buying an additional 11,500 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in NovoCure Limited in the 2nd quarter worth $362,000. Institutional investors and hedge funds own 36.21% of the company’s stock.

A number of brokerages have weighed in on NVCR. Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub upgraded shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Mizuho began coverage on shares of NovoCure Limited in a report on Wednesday, September 6th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 price target (down previously from $29.00) on shares of NovoCure Limited in a report on Friday, October 27th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. NovoCure Limited has a consensus rating of “Buy” and an average target price of $21.00.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply